Immunotherapies

Researchers identify cell surface protein DLK1 as a potential immunotherapeutic target for neuroblastoma.

Leyuan Ma, PhD, our October Faculty Spotlight, uses his passion for immune engineering to develop novel therapeutic treatments for cancer.